Healthcare Industry News: stereotactic radiation therapy
News Release - October 29, 2007
TomoTherapy and Medical Intelligence Announce Strategic Partnership at ASTROCompanies Preview Jointly Developed Fixation and Repositioning Device for CT-Guided, Helical Stereotactic Radiosurgery
MADISON, Wis.--(HSMN NewsFeed)--TomoTherapy Incorporated (NASDAQ:TTPY ) announced today that it has partnered with Medical Intelligence, an Elekta company, to enhance the TomoTherapy® Hi·Art® treatment system’s stereotactic radiosurgery capabilities. A head frame fixation and repositioning device, is on display in the TomoTherapy booth at the Annual Meeting of the American Society of Therapeutic Radiology and Oncology (ASTRO), which opened Sunday and runs through Wednesday, October 31, 2007. This is a works-in-progress prototype of the first product to be developed through the partnership.
“We are pleased to welcome Medical Intelligence as a strategic partner,” said Del Coufal, vice president of marketing for TomoTherapy. “Medical Intelligence joins a number of companies who have signed on to develop products for the Hi·Art treatment system. As providers of this next-generation platform, it is important for TomoTherapy to work with industry innovators as we deliver the tools our customers need to continue advancing the state of cancer care.”
Since 2003, more than 150 TomoTherapy Hi·Art treatment systems have been installed in cancer treatment centers around the world. The system is unique among radiation therapy devices because it integrates CT imaging and a helical delivery pattern for increased accuracy and precision of intensity-modulated radiation therapy (IMRT). Increasingly, clinicians have also used the Hi·Art system for stereotactic radiosurgery (SRS) and stereotactic radiation therapy (SRT), where high doses of precisely targeted radiation are delivered in a single or a few treatment fractions.
Said Christian Hieronimi, managing director of Medical Intelligence, “We see this as an excellent opportunity to help enhance the clinical functionality of the TomoTherapy Hi·Art system. In combination with our equipment and expertise in the SRS field, more patients worldwide will benefit from the TomoTherapy treatment process.”
About Medical Intelligence
Medical Intelligence, part of the Elekta Group, is a world-leading supplier of advanced and innovative radiation oncology and interventional guidance products for precise and reliable patient positioning. Our product lines include among others non-invasive immobilisation and positioning systems, robotic treatment couches and targeting devices.
Rigorous radiation therapy treatment modalities require precise patient positioning and immobilisation. Medical Intelligence radiation therapy solutions are engineered to fit today’s requirements for image guided radiation therapy (IGRT) and precise radiation therapy from diagnostics through treatment.
Medical Intelligence is a small, entrepreneurial, customer-focused company that provides the tools to enable precise patient positioning and immobilisation while maintaining patient comfort and confidence.
About TomoTherapy Incorporated
TomoTherapy Incorporated has developed, manufactures and sells the TomoTherapy® Hi·Art® treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi·Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company completed its initial public offering in May 2007 and its stock is traded on the NASDAQ Global Market under the symbol TTPY. To learn more about TomoTherapy, please visit our Web site at www.TomoTherapy.com.
Statements in this release regarding future products, events, expectations and other similar matters, including but not limited to statements using the terms “can,” “will” or “expect” constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including but not limited to risks inherent in the development and commercialization of new technology and products, and the other risks listed from time to time in TomoTherapy’s filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. These forward-looking statements represent TomoTherapy’s judgments as of this date of this press release. TomoTherapy assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events or otherwise.
TomoTherapy, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.